1.Induction of prolongation of allograft survival by immunization with immature DCS
Chinese Journal of Immunology 1985;0(06):-
Objective:To prolong the allograft survival time in immunized mice with immature dendritic cell, and to analyze the mechanism of hypo allo immuno responsiveness induced by immature dendritic cells Methods:Based on mouse cardiac allograft model, the survival of cardiac recipients immunized with mature or immature DC were observed Meanwhile the CTL activity of splenocytes from immature DC immunized recipients was detected Results:The survival time of cardiac allograft was substantially prolonged and the mean survival time extended from 9 1?0 73 days to 25 4?4 27 days It became more effective if those immunized mice were treated in combination with adriamycin application, the mean survival time of allograft was extended to 30 5?3 98 days It was proved that the CTL activity in spleen cells from the mice immunized with immature DCs was much lower (specific release was 16 32%) than that from the immunized mice with mature DCs (specific release was 39 58%) Conclusion:Immature DCs could induce prolongation of allograft survival time It may be possible that low CTL activity in recipients immunized with immature DCs promised this prolongation
2.Study on antitumor effect of dendritic cells against Lewis lung cancer
Wenfei YE ; Qianggang DONG ; Qiuzao HE ; Al ET
Chinese Journal of Immunology 1985;0(03):-
Objective:To study anti tumor immunity against Lewis lung cancer of dendritic cells derived from proliferated bone marrow cells Methods:After immunization with MUT 1 peptide pulsed DCs (DC MUT 1) intravenously, C57BL/6 mice were challenged with tumor cells subcutaneously to test the immune protection effect Meanwhile, CTL assay was analyzed Results:DC MUT 1 could induce durable and specific antitumor immunity in mice, and the T cells from immunized mice with pulsed DCs showed strong CTL activity Conclusion: An antitumor cellular immunity and a specific immune protection could be induced by immunization with DC MUT 1
3.The long lasting effect of the murine fibroblast growth factor-21 on blood glucose control of diabetic animals.
Jingzhuang ZHAO ; Guopeng SUN ; Xianlong YE ; Jinnan LI ; Guiping REN ; Wenfei WANG ; Mingyao LIU ; Deshan LI
Acta Pharmaceutica Sinica 2013;48(3):352-8
Insulin is the most common medicine used for diabetic patients, unfortunately, its effective time is short, even the long-acting insulin cannot obtain a satisfactory effect. Fibroblast growth factor (FGF)-21 is a recently discovered glucose mediator and expected to be a potential anti-diabetic drug that does not rely on insulin. In this study, db/db mice were used as the type 2 diabetic model to examine whether mFGF-21 has the long-term blood lowering effect on the animal model. The results showed that mFGF-21 could stably maintain the blood glucose at normal level for a long-term in a dose-dependent manner. Administration of mFGF-21 once a day with three doses (0.125, 0.25 and 0.5 mg x kg(-1)) could maintain blood glucose of the model animals at normal level for at least 24 h. Administration of mFGF-21 every two days with the same doses could maintain blood glucose of the model animals at normal level for at least 48 h, although it took longer time for blood glucose to reach to normal level depending on doses used (twenty injections for 0.125 mg x kg(-1) and 0.25 mg x kg(-1) doses, ten injections for 0.5 mg x kg(-1) dose). Surprisingly, the blood glucose of the treated model animals still maintained at normal level for 24 h after the experiment terminated. Glycosylated hemoglobin level of the animals treated with mFGF-21, which represented long-term glucose status, decreased significantly compared to the control group and the insulin group. The results suggest that FGF-21 has potential to become a long-acting and potent anti-diabetic drug.
4.Preparation and penetrating effect of the polyarginine-enhanced green fluorescence protein fusion protein.
Nan ZHANG ; Yin BAI ; Jingzhuang ZHAO ; Xianlong YE ; Wenfei WANG ; Guiping REN ; Deshan LI ; Yan JING
Chinese Journal of Biotechnology 2013;29(11):1644-1653
The aim of the study is to establish a platform to deliver therapeutic proteins into target cells through a polyarginine-based cell penetrating peptide. To facilitate the expression of therapeutic proteins, a pSUMO (Small Ubiquitin-like Modifier)-R9-EGFP (enhanced green fluorescence protein) prokaryotic expression vector was constructed. After induction, the fusion protein SUMO-R9-EGFP was efficiently expressed. To validate the cell penetrating ability of the fusion protein, HepG2 cells were incubated with the purified R9-EGFP or EGFP protein as control, internalization of the fluorescent proteins was examined by either flow cytometry or confocal microscopy. The result obtained by flow cytometry showed that the R9-EGFP fusion protein could efficiently penetrate into the HepG2 cells in a dose and time-dependent manner. In contrast, the fluorescence was barely detected in the HepG2 cells incubated with EGFP control. The fluorescence intensity of the R9-EGFP treated cells reached plateau phase after 1.5 h. The result obtained by confocal microscopy shows that R9-EGFP efficiently entered into the HepG2 cells and was exclusively located in the cytoplasm, whereas, no fluorescence was detected in the cells incubated with the EGFP control. The heparin inhibition experiment showed that heparin could inhibit penetrating effect of the R9-EGFP protein by about 50%, suggesting that the penetrating ability of the fusion protein is heparin-dependent. In summary, the study has established a platform to deliver therapeutic proteins into target cells through a polyarginine-based penetrating peptide.
Cell-Penetrating Peptides
;
biosynthesis
;
genetics
;
pharmacology
;
Genetic Vectors
;
genetics
;
Green Fluorescent Proteins
;
biosynthesis
;
genetics
;
Hep G2 Cells
;
Humans
;
Peptides
;
genetics
;
metabolism
;
Protein Transport
;
Recombinant Fusion Proteins
;
biosynthesis
;
genetics
;
pharmacology
5.Therapeutic effect of fibroblast growth factor 21 on hypertension induced by insulin resistance.
Shenglong ZHU ; Guiping REN ; Zhenyu ZHANG ; Wenfei WANG ; Xianlong YE ; Miaomiao HAN ; Jingzhuang ZHAO ; Tongyu XU ; Mingyao LIU ; Deshan LI
Acta Pharmaceutica Sinica 2013;48(9):1409-14
This study is to evaluate the therapeutic effect of fibroblast growth factor 21 (FGF21) on hypertension induced by insulin resistance in rats and to provide mechanistic insights into its therapeutic effect. Male Sprague-Dawley (SD) rats were fed with high-fructose (10%) water to develop mild hypertensive models within 4 weeks, then randomized into 4 groups: model control, FGF21 0.25, 0.1 and 0.05 micromol x kg(-1) x d(-1) groups. Five age-matched normal SD rats administrated with saline were used as normal controls. The rats in each group were treated once a day for 4 weeks. Body weight was measured weekly, systolic blood pressure (SBP) was measured noninvasively using a tail-cuff method, insulin sensitivity was assessed using oral glucose tolerance test (OGTT) and HOMA-IR assay. At the end of the treatment, blood samples were collected, and blood glucose, serum cholesterol, serum triglyceride and serum insulin were measured. The results showed that blood pressure of the rats treated with different doses of FGF21 returned to normal levels [(122.2 +/- 3.5) mmHg, P < 0.01] after 4-week treatment, whereas, SBP of untreated (model control) rats maintained a high level [(142.5 +/- 4.5) mmHg] throughout the treatment. The observation of blood pressure in 24 h revealed that SBP of FGF21 treated-rats maintained at (130 +/- 4.5) mmHg vs. (143 +/- 5.5) mmHg for model control (P < 0.01). FGF21 treatment groups improved serum lipids obviously, total cholesterol (TC) and triglyceride (TG) levels decreased significantly to normal levels. The serum NO levels of three different doses FGF21 treatment group were significantly higher than that of the model control group [(7.32 +/- 0.11), (7.24 +/- 0.13), (6.94 +/- 0.08) vs. (6.56 +/- 0.19) micromol x L(-1), P < 0.01], and the degree of improvement showed obvious dose-dependent manner, indicating that FGF21 can significant increase serum NO in fructose-induced hypertension rat model and improve endothelial NO release function. The results of OGTT and HOMA-IR showed that insulin resistance state was significantly relieved in a dose-dependent manner. Thus, this study demonstrates that FGF21 significantly ameliorates blood pressure in fructose-induced hypertension model by relieving insulin resistance. This finding provides a theoretical support for clinical application of FGF21 as a novel therapeutics for treatment of essential hypertension.
6.Effect of FGF-21 on learning and memory ability and antioxidant capacity in brain tissue of D-galactose-induced aging mice.
Yinhang YU ; Guiping REN ; Yaonan LIU ; Susu QU ; Fuliang BAI ; Tong ZHANG ; Wenfei WANG ; Guiyou TIAN ; Xianlong YE ; Deshan LI
Acta Pharmaceutica Sinica 2014;49(7):1000-6
This study aims to investigate the effects of fibroblast growth factor 21 (FGF-21) on learning and memory abilities and antioxidant capacity of D-galactose-induced aging mice. Kunming mice (37.1 +/- 0.62) g were randomly divided into normal control group, model group and FGF-21 high, medium and low dose groups (n = 8). Each group was injected in cervical part subcutaneously with D-galactose 180 mg x kg(-1) x d(-1) once a day for 8 weeks. At the same time, FGF-21-treated mice were administered with FGF-21 by giving subcutaneous injection in cervical part at the daily doses of 5, 2 and 1 mg x kg(-1) x d(-1). The normal control group was given with normal saline by subcutaneous injection in cervical part. At seventh week of the experiment, the learning and memory abilities of mice were determined by water maze and jumping stand tests. At the end of the experiment, the mice were sacrificed and the cells damage of hippocampus was observed by HE staining in each group. Reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) and total antioxidant capacity (T-AOC) in the brain of mice were determined. The results showed that different doses of FGF-21 could reduce the time reaching the end (P < 0.01 or P < 0.05) and the number of touching blind side (P < 0.01 or P < 0.05) in the water maze comparing with the model group. It could also prolong the latency time (P < 0.05) and decrease the number of errors (P < 0.01 or P < 0.05) in the step down test. The result of HE staining showed that FGF-21 could significantly reduce brain cell damage in the hippocampus. The ROS and MDA levels of three different doses FGF-21 treatment group reduced significantly than that of the model group [(5.58 +/- 1.07), (7.78 +/- 1.92), (9.03 +/- 1.77) vs (12.75 +/- 2.02) pmol (DCF) x min(-1) x mg(-1), P < 0.01 or P < 0.05], [(2.92 +/- 0.71), (4.21 +/- 0.81), (4.41 +/- 0.97) vs (5.62 +/- 0.63) nmol x mg(-1) (protein), P < 0.01]. Comparing with the model group, the activities of SOD, GPx, CAT and T-AOC of the three different doses FGF-21 treatment groups were also improved in a dose-dependent manner. This study demonstrates that FGF-21 can ameliorate learning and memory abilities of D-galactose induced aging mice, improve the antioxidant abilities in brain tissue and delay brain aging. This finding provides a theoretical support for clinical application of FGF-21 as a novel therapeutics for preventing aging.
7.Optimization and characterization of a novel FGF21 mutant.
Xianlong YE ; Huashan GAO ; Wenfei WANG ; Guiping REN ; Mingyao LIU ; Kun HE ; Yakun ZHANG ; Jingzhuang ZHAO ; Dan YU ; Deshan LI
Acta Pharmaceutica Sinica 2012;47(7):897-903
Fibroblast growth factor 21 (FGF21) is a member of FGF family. It has been demonstrated that FGF21 is an independent, safe and effective regulator of blood glucose levels in vivo. In order to improve the activity of FGF21, we exchanged the beta10-beta12 domain of the human FGF21 with that of the mouse FGF21 to construct a novel FGF21 gene (named hmFGF21), and then subcloned hmFGF21 gene into the SUMO expression vector to create pSUMO-hmFGF21 and transformed it into E. coli Rosetta for expression of the fusion protein SUMO-hmFGF21. Both in vitro and in vivo glucose regulation activity of hmFGF21 was evaluated. The SDS-PAGE result showed that compared with wild-type hFGF21, the soluble expression of hmFGF21 increased about 2-fold. HmFGF21 was more potent in stimulation of glucose uptake in HepG2 cells in vitro. The results of anti-diabetic effect on db/db mice demonstrated that hmFGF21 had better efficacy on controlling the blood glucose of the db/db diabetic animals than wild-type hFGF21. These results suggest that the biological properties of FGF21 are significantly improved by optimization.
8.A randomized controlled trial of laparoscopic vs open radical nephrectomy for renal cancer
Jun YAN ; Hui YU ; Mingang YING ; Dong ZHOU ; Xia CHEN ; Luchuan CHEN ; Wenfei YE ; Weidang ZANG ; Chunkang YANG ; Xiaojing CHEN ; Lingping WANG
Chinese Journal of Urology 2010;31(7):449-451
Objective To compare the therapeutic outcomes between laparoscopic radical Rephrectomy and open radical nephrectomy for renal cancer. Methods A prospective randomized controlled trial was performed in Fujian Provincial Tumor Hospital from January 2006 to July 2009.Sixty-two cases were randomly divided into 2 groups:laparoscopic radical nephrectomy and open radical nephrectomy.Primary outcome(post-operative hospital stay)and second outcome(estimated blood loss,operative time,incision length,post-operative complications,recurrence,metastasis and survival)were compared between 2 groups. Results Post-operative hospital stay was(5.4±1.3)d in laparoscopic group and(8.1±2.2)d in open group(P<0.05).Median estimated blood loss was 100 ml in laparoseopic group and 200 ml in open group(P<0.05).There were no significant difference between teh 2 groups in operative time,post-operative complications,recurrence,metastasis and survival rates(P>0.05). Conclusion Laparoscopic nephrectomy could reduce hospital stay,which provides a minimally invasive approach for renal cancer.
9.The synergistic effect of FGF-21 and insulin on regulating glucose metabolism and its mechanism.
Dan YU ; Cuiyu SUN ; Guopeng SUN ; Guiping REN ; Xianlong YE ; Shenglong ZHU ; Wenfei WANG ; Pengfei XU ; Shujie LI ; Qiang WU ; Zeshan NIU ; Tian SUN ; Mingyao LIU ; Deshan LI
Acta Pharmaceutica Sinica 2014;49(7):977-84
Previous studies proposed that the synergistic effect of fibroblast growth factor-21 (FGF-21) and insulin may be due to the improvement of insulin sensitivity by FGF-21. However, there is no experimental evidence to support this. This study was designed to elucidate the mechanism of synergistic effect of FGF-21 and insulin in the regulation of glucose metabolism. The synergistic effect of FGF-21 and insulin on regulating glucose metabolism was demonstrated by investigating the glucose absorption rate by insulin resistance HepG2 cell model and the blood glucose chances in type 2 diabetic db/db mice after treatments with different concentrations of FGF-21 or/and insulin; The synergistic metabolism was revealed through detecting GLUT1 and GLUT4 transcription levels in the liver by real-time PCR method. The experimental results showed that FGF-21 and insulin have a synergistic effect on the regulation of glucose metabolism. The results of real-time PCR showed that the effective dose of FGF-21 could up-regulate the transcription level of GLUT1 in a dose-dependent manner, but had no effect on the transcription level of GLUT4. Insulin (4 u) alone could up-regulate the transcription level of GLUT4, yet had no effect on that of GLUT1. Ineffective dose 0.1 mg kg(-1) FGF-21 alone could not change the transcription level of GLUT1 or GLUT4. However, when the ineffective dose 0.1 mg x kg(-1) FGF-21 was used in combination with insulin (4 u) significantly increased the transcription levels of both GLUT1 and GLUT4, the transcription level of GLUT1 was similar to that treated with 5 time concentration of FGF-21 alone; the transcription level of GLUT4 is higher than that treated with insulin (4 u) alone. In summary, in the presence of FGF-21, insulin increases the sensitivity of FGF-21 through enhancing GLUT1 transcription. Vice versa, FGF-21 increases the sensitivity of insulin by stimulating GLUT4 transcription in the presence of insulin. FGF-21 and insulin exert a synergistic effect on glucose metabolism through mutual sensitization.
10.Exercising the oropharyngeal muscles can help alleviate moderate obstructive sleep apnea among stroke survivors
Dongmei YE ; Chen CHEN ; Mei SHEN ; Hongwei LIU ; Liang WANG ; Surui ZHANG ; Hong ZHANG ; Jingya LI ; Wenfei YU ; Wei WANG
Chinese Journal of Physical Medicine and Rehabilitation 2018;40(8):583-587
Objective To observe the efficacy of oropharyngeal muscle exercise for relieving obstructive sleep apnea (OSAS) among stroke survivors.Methods Fifty stroke survivors with moderate OSAS were randomly divided into an observation group and a control group,each of 25.Both groups were given routine drugs and rehabilitation,while the observation group was additionally provided with oropharyngeal muscle exercises during the daytime for 20 minutes twice a day for6 weeks.The control group received deep breathing therapy.Before and after the 6 weeks of treatment,both groups were evaluated using polysomnography.Their sleep quality and daytime sleepiness were measured using the Pittsburgh sleep quality index and the Stanford sleepiness scale.Any changes in the patients' pharyngeal morphology after exercise were evaluated using MRI.Results After the oropharyngeal muscle exercises,the apnea hypoventilation index and minimum SaO2 %,the snore index and sleep quality improved significantly.Daytime sleepiness was significantly relieved.Some structural remodeling of the pharyngeal airvay was observed by MRI,including significantly larger retropalatal distance and shorter length of the soft palate.The retropalatal distance was positively and correlated with the duration of exercise while the length of soft palate correlated negatively.Conclusion Exercising the oropharyngeal muscles is a promising alternative treatment for stroke survivors with moderate OSAS.It improves the morphology of the oropharynx to relieve obstruction during sleeping.